Early modeling put sickle cell gene therapy coverage near 11 cents per member per month.
|Articles|February 13, 2013
Fact Checker: Medicare Reform
Advertisement
“On Medicare, I’m prepared to enact reforms that will achieve the same amount of health care savings by the beginning of the next decade as the reforms proposed by the bipartisan Simpson-Bowles commission. “
This carefully crafted phrase recently earned the president a Geppetto Checkmark. Obama wants us to compare the savings in 2022. Granted, that would be six years after Obama’s second term ends. But administration officials argue that changes in health-care policies take time to achieve budget savings, and that the right mix can produce greater savings in the long run.
Read the full story:
Source: The Washington Post
Advertisement
Related to this article
Claims data show evidence of HIV virus in 5 of 2913 long-acting cabotegravir users and higher adherence vs oral therapy.
Experts at AMCP Nexus say biosimilar launches should prompt payers to revisit step therapy and measure value beyond market share.
Three experts apply policy, pharmacy operations, and member-level lenses to the same prescriptions to show why cost at the counter decides adherence.
Most Medicaid unwinding losses were procedural. mPulse's SriVani Ganti explains how plans can keep eligible members.
Elagolix 150 mg was noninferior to dienogest 2 mg for reducing moderate-to-severe endometriosis pain in a phase 3 trial of 230 women in India.
Initial frontal fibrosing alopecia treatment was largely similar in Black and White patients, though tetracycline use was higher in Black patients.
Nearly half of patients with chronic HBV or HCV also had MASLD, tied to worse fatigue and quality of life.
Advertisement
Advertisement
Trending on AJMC
1
New Data Link Cabotegravir PrEP to Few HIV Cases, Higher Adherence
2
HHS Draft Policy Eases Enforcement on 6 Compounded Peptides
3
BPC-157 'Wolverine Peptide' Use Rose 33-Fold Despite Scant Evidence
4
Biosimilar Entry Should Trigger a Fresh Look at Biologic Access
5